EGFR and non-small cell lung carcinoma: However, it was demonstrated that EGFR mutation status did not limit the improvement in OS for advanced NSCLC with high EGFR expression upon treatment with combination cetuximab plus chemotherapy (oxaliplatin plus vinorelbine) [123].